George Makavos, Ignatios Ikonomidis, Vaia Lambadiari, Georgia-Angeliki Koliou, George Pavlidis, John Thymis, Pinelopi Rafouli-Stergiou, Gavriella Kostelli, Konstantinos Katogiannis, Konstantinos Stamoulis, Aikaterini Kountouri, Emmanouil Korakas, Kostas Theodoropoulos, Alexandra Frogoudaki, Pelagia Katsimbri, Evangelia Papadavid
{"title":"纵向心肌变形与 SCORE2 对银屑病预后的叠加价值","authors":"George Makavos, Ignatios Ikonomidis, Vaia Lambadiari, Georgia-Angeliki Koliou, George Pavlidis, John Thymis, Pinelopi Rafouli-Stergiou, Gavriella Kostelli, Konstantinos Katogiannis, Konstantinos Stamoulis, Aikaterini Kountouri, Emmanouil Korakas, Kostas Theodoropoulos, Alexandra Frogoudaki, Pelagia Katsimbri, Evangelia Papadavid","doi":"10.1093/ehjopen/oead016","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Psoriasis has been associated with increased cardiovascular (CV) risk. We investigated whether markers of CV function and their change after treatment have a prognostic value for adverse outcomes.</p><p><strong>Methods and results: </strong>In a prospective study, at baseline and after 6 months of treatment with biological agents, we assessed in 298 psoriasis patients (i) left ventricular global longitudinal strain (GLS) and (ii) carotid-femoral pulse wave velocity (PWV), to evaluate their prognostic value for major adverse cardiovascular events (MACEs), including coronary artery disease, stroke, hospitalization for heart failure, and all-cause death over a 4-year follow-up period. During follow-up, 26 (8.7%) MACEs were recorded. By univariate analysis, decreasing absolute GLS values [hazard ratio (HR): 0.73, <i>P</i> < 0.001], decreasing GLS change after treatment (HR: 0.53, <i>P</i> = 0.008), and increasing PWV values (HR: 1.16, <i>P</i> = 0.049) were associated with adverse outcomes. Baseline GLS and its change post-treatment remained independent predictors of adverse events after adjusting for several confounders (<i>P</i> < 0.05). The addition of baseline GLS and its absolute change post-treatment to SCORE2 increased Harrell's <i>C</i> from 0.882 to 0.941. By multivariable analysis, for each 1% increase in absolute baseline GLS values, the risk of MACE decreased by 33% and for each 1% absolute increase of GLS post-treatment compared with the baseline value, the risk of MACE decreased by 58%.</p><p><strong>Conclusion: </strong>Global longitudinal strain has an independent and additive prognostic value to SCORE2 for adverse CV events in psoriasis, providing timely decision-making for intensive anti-inflammatory treatment and aggressive modification of risk factors to reduce CV risk.</p>","PeriodicalId":11973,"journal":{"name":"European Heart Journal Open","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023827/pdf/","citationCount":"0","resultStr":"{\"title\":\"Additive prognostic value of longitudinal myocardial deformation to SCORE2 in psoriasis.\",\"authors\":\"George Makavos, Ignatios Ikonomidis, Vaia Lambadiari, Georgia-Angeliki Koliou, George Pavlidis, John Thymis, Pinelopi Rafouli-Stergiou, Gavriella Kostelli, Konstantinos Katogiannis, Konstantinos Stamoulis, Aikaterini Kountouri, Emmanouil Korakas, Kostas Theodoropoulos, Alexandra Frogoudaki, Pelagia Katsimbri, Evangelia Papadavid\",\"doi\":\"10.1093/ehjopen/oead016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Psoriasis has been associated with increased cardiovascular (CV) risk. We investigated whether markers of CV function and their change after treatment have a prognostic value for adverse outcomes.</p><p><strong>Methods and results: </strong>In a prospective study, at baseline and after 6 months of treatment with biological agents, we assessed in 298 psoriasis patients (i) left ventricular global longitudinal strain (GLS) and (ii) carotid-femoral pulse wave velocity (PWV), to evaluate their prognostic value for major adverse cardiovascular events (MACEs), including coronary artery disease, stroke, hospitalization for heart failure, and all-cause death over a 4-year follow-up period. During follow-up, 26 (8.7%) MACEs were recorded. By univariate analysis, decreasing absolute GLS values [hazard ratio (HR): 0.73, <i>P</i> < 0.001], decreasing GLS change after treatment (HR: 0.53, <i>P</i> = 0.008), and increasing PWV values (HR: 1.16, <i>P</i> = 0.049) were associated with adverse outcomes. Baseline GLS and its change post-treatment remained independent predictors of adverse events after adjusting for several confounders (<i>P</i> < 0.05). The addition of baseline GLS and its absolute change post-treatment to SCORE2 increased Harrell's <i>C</i> from 0.882 to 0.941. By multivariable analysis, for each 1% increase in absolute baseline GLS values, the risk of MACE decreased by 33% and for each 1% absolute increase of GLS post-treatment compared with the baseline value, the risk of MACE decreased by 58%.</p><p><strong>Conclusion: </strong>Global longitudinal strain has an independent and additive prognostic value to SCORE2 for adverse CV events in psoriasis, providing timely decision-making for intensive anti-inflammatory treatment and aggressive modification of risk factors to reduce CV risk.</p>\",\"PeriodicalId\":11973,\"journal\":{\"name\":\"European Heart Journal Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023827/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Heart Journal Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/ehjopen/oead016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ehjopen/oead016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Additive prognostic value of longitudinal myocardial deformation to SCORE2 in psoriasis.
Aims: Psoriasis has been associated with increased cardiovascular (CV) risk. We investigated whether markers of CV function and their change after treatment have a prognostic value for adverse outcomes.
Methods and results: In a prospective study, at baseline and after 6 months of treatment with biological agents, we assessed in 298 psoriasis patients (i) left ventricular global longitudinal strain (GLS) and (ii) carotid-femoral pulse wave velocity (PWV), to evaluate their prognostic value for major adverse cardiovascular events (MACEs), including coronary artery disease, stroke, hospitalization for heart failure, and all-cause death over a 4-year follow-up period. During follow-up, 26 (8.7%) MACEs were recorded. By univariate analysis, decreasing absolute GLS values [hazard ratio (HR): 0.73, P < 0.001], decreasing GLS change after treatment (HR: 0.53, P = 0.008), and increasing PWV values (HR: 1.16, P = 0.049) were associated with adverse outcomes. Baseline GLS and its change post-treatment remained independent predictors of adverse events after adjusting for several confounders (P < 0.05). The addition of baseline GLS and its absolute change post-treatment to SCORE2 increased Harrell's C from 0.882 to 0.941. By multivariable analysis, for each 1% increase in absolute baseline GLS values, the risk of MACE decreased by 33% and for each 1% absolute increase of GLS post-treatment compared with the baseline value, the risk of MACE decreased by 58%.
Conclusion: Global longitudinal strain has an independent and additive prognostic value to SCORE2 for adverse CV events in psoriasis, providing timely decision-making for intensive anti-inflammatory treatment and aggressive modification of risk factors to reduce CV risk.